HR 946 — ORPHAN Cures Act
Congress 119
Latest action: — Sponsor introductory remarks on measure. (CR H535-536)
Sponsors
- Salinas, Andrea (D, OR-6) — cosponsor
- Hern, Kevin (R, OK-1) — cosponsor
- Davis, Donald G. (D, NC-1) — cosponsor
- Gray, Adam (D, CA-13) — cosponsor
- Thanedar, Shri (D, MI-13) — cosponsor
Lobbied by (10)
LDA filings that named this bill in their activity descriptions. The lobbying firm (registrant) is paid by the client to lobby on this and related issues.
| Filing | Period | Registrant (lobbying firm) | Client | Income | Matched |
|---|---|---|---|---|---|
| 1st Quarter - Report | 2026 first_quarter | TIBER CREEK GROUP | INCYTE CORPORATION | $80,000 | H.R. 946 |
| 1st Quarter - Report | 2026 first_quarter | TIBER CREEK GROUP | EMD SERONO, INC. | $50,000 | H.R. 946 |
| 1st Quarter - Report | 2026 first_quarter | TIBER CREEK GROUP | ASTRAZENECA | $80,000 | H.R. 946 |
| 1st Quarter - Report | 2026 first_quarter | W STRATEGIES, LLC | INCYTE CORPORATION | $60,000 | H.R.946 |
| 1st Quarter - Report | 2026 first_quarter | W STRATEGIES, LLC | CALIFORNIA LIFE SCIENCES | $40,000 | H.R.946 |
| 1st Quarter - Report | 2026 first_quarter | TIBER CREEK GROUP | ALNYLAM PHARMACEUTICALS, INC. | $60,000 | H.R. 946 |
| 1st Quarter - Report | 2026 first_quarter | LMH STRATEGIC SOLUTIONS | IONIS PHARMACEUTICALS, INC. | $30,000 | H.R.946 |
| 1st Quarter - Report | 2026 first_quarter | LMH STRATEGIC SOLUTIONS | ALNYLAM PHARMACEUTICALS, INC. | $50,000 | H.R.946 |
| 1st Quarter - Report | 2026 first_quarter | LMH STRATEGIC SOLUTIONS | ALKERMES, INC. | $60,000 | H.R.946 |
| 1st Quarter - Report | 2026 first_quarter | LUNDBECK LLC | LUNDBECK LLC | — | H.R. 946 |
Action timeline
- · H11100 — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- · H11100 — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- · Intro-H — Introduced in House
- · 1000 — Introduced in House
- · B00100 — Sponsor introductory remarks on measure. (CR H535-536)
Text versions
- Introduced in House · 2025-02-04 — open
Connected on the graph
Inbound (15)
| date | from | type | amount | role | source |
|---|---|---|---|---|---|
| — | Salinas, Andrea | cosponsor_of_bill | — | cosponsor | sponsorship |
| — | Davis, Donald G. | cosponsor_of_bill | — | cosponsor | sponsorship |
| — | Hern, Kevin | cosponsor_of_bill | — | cosponsor | sponsorship |
| — | Gray, Adam | cosponsor_of_bill | — | cosponsor | sponsorship |
| — | Thanedar, Shri | cosponsor_of_bill | — | cosponsor | sponsorship |
| 2026-01-01 | LUNDBECK LLC | lobbies_on_bill | — | H.R. 946 | lobbying_bill_mention |
| 2026-01-01 | ALNYLAM PHARMACEUTICALS, INC. | lobbies_on_bill | — | H.R. 946 | lobbying_bill_mention |
| 2026-01-01 | IONIS PHARMACEUTICALS, INC. | lobbies_on_bill | — | H.R.946 | lobbying_bill_mention |
| 2026-01-01 | ASTRAZENECA | lobbies_on_bill | — | H.R. 946 | lobbying_bill_mention |
| 2026-01-01 | ALKERMES, INC. | lobbies_on_bill | — | H.R.946 | lobbying_bill_mention |
| 2026-01-01 | INCYTE CORPORATION | lobbies_on_bill | — | H.R.946 | lobbying_bill_mention |
| 2026-01-01 | EMD SERONO, INC. | lobbies_on_bill | — | H.R. 946 | lobbying_bill_mention |
| 2026-01-01 | ALNYLAM PHARMACEUTICALS, INC. | lobbies_on_bill | — | H.R.946 | lobbying_bill_mention |
| 2026-01-01 | CALIFORNIA LIFE SCIENCES | lobbies_on_bill | — | H.R.946 | lobbying_bill_mention |
| 2026-01-01 | INCYTE CORPORATION | lobbies_on_bill | — | H.R. 946 | lobbying_bill_mention |
Outbound (2)
| date | type | to | amount | role | source |
|---|---|---|---|---|---|
| 2025-01-03 | referred_to_committee | House Ways and Means Committee | — | congress-committee | |
| 2025-01-03 | referred_to_committee | House Energy and Commerce Committee | — | congress-committee |
Who matters
Members ranked by combined influence on this bill: role (sponsor 5 / cosponsor 1), capped speech count from the Congressional Record, and recorded-vote engagement.
| # | Member | Role | Speeches | Voted | Score |
|---|---|---|---|---|---|
| 1 | Davis, Donald G. (D, house NC-1) | cosponsor | 3 | — | 4 |
| 2 | Gray, Adam (D, house CA-13) | cosponsor | 1 | — | 2 |
| 3 | Salinas, Andrea (D, house OR-6) | cosponsor | 1 | — | 2 |
| 4 | Hern, Kevin (R, house OK-1) | cosponsor | 0 | — | 1 |
| 5 | Thanedar, Shri (D, house MI-13) | cosponsor | 0 | — | 1 |
Who's influencing them
Orgs ranked by combined money flow on this bill: LDA filings citing the bill + individual contributions in cycle 2026from donors whose employer matches the org name (Schedule A) to any principal committee in the "who matters" list above.
| # | Org | LDA filings | LDA spend | Donor employees | Employee donations | Total |
|---|---|---|---|---|---|---|
| 1 | INCYTE CORPORATION | 2 | $140,000 | 0 | $0 | $140,000 |
| 2 | ALNYLAM PHARMACEUTICALS, INC. | 2 | $110,000 | 0 | $0 | $110,000 |
| 3 | ASTRAZENECA | 1 | $80,000 | 0 | $0 | $80,000 |
| 4 | ALKERMES, INC. | 1 | $60,000 | 0 | $0 | $60,000 |
| 5 | EMD SERONO, INC. | 1 | $50,000 | 0 | $0 | $50,000 |
| 6 | CALIFORNIA LIFE SCIENCES | 1 | $40,000 | 0 | $0 | $40,000 |
| 7 | IONIS PHARMACEUTICALS, INC. | 1 | $30,000 | 0 | $0 | $30,000 |
| 8 | not employed | 0 | $0 | 92 | $14,969 | $14,969 |
| 9 | dragonfly | 0 | $0 | 1 | $7,000 | $7,000 |
| 10 | berkshire partners | 0 | $0 | 1 | $7,000 | $7,000 |
| 11 | university of california berkeley | 0 | $0 | 1 | $5,000 | $5,000 |
| 12 | method security | 0 | $0 | 1 | $3,500 | $3,500 |
| 13 | self employed | 0 | $0 | 11 | $3,233 | $3,233 |
| 14 | thorsen french advocacy | 0 | $0 | 2 | $3,000 | $3,000 |
| 15 | united states hispanic business counci | 0 | $0 | 1 | $2,500 | $2,500 |
| 16 | tabula rasa farms | 0 | $0 | 1 | $2,500 | $2,500 |
| 17 | healthcare | 0 | $0 | 1 | $2,000 | $2,000 |
| 18 | tpg partners | 0 | $0 | 1 | $1,500 | $1,500 |
| 19 | canada life reinsurance company | 0 | $0 | 1 | $1,250 | $1,250 |
| 20 | canada life re : for the acli ceo even | 0 | $0 | 1 | $1,250 | $1,250 |
| 21 | martin fein interests, ltd. | 0 | $0 | 1 | $1,000 | $1,000 |
| 22 | mcgillivary steele elkin | 0 | $0 | 1 | $1,000 | $1,000 |
| 23 | the sterling group | 0 | $0 | 1 | $1,000 | $1,000 |
| 24 | ever.ag | 0 | $0 | 1 | $1,000 | $1,000 |
| 25 | raizner slania llp | 0 | $0 | 1 | $1,000 | $1,000 |
Predicted vote
Aggregated from: actual roll-call votes (when present) → sponsor → cosponsor → party median (predicts YES when ≥25% of the caucus sponsored/cosponsored). Each row labels its confidence tier so you can see why a position was predicted.
5 predicted yes (1%) · 3 predicted no (1%) · 535 unknown (98%)
By party: · R: 1 yes / 0 no / 276 unknown · D: 4 yes / 0 no / 259 unknown · I: 0 yes / 3 no
5 high-confidence positions (voted + sponsor + cosponsor)
- Davis, Donald G. (D · house · NC-1) · cosponsor
- Gray, Adam (D · house · CA-13) · cosponsor
- Hern, Kevin (R · house · OK-1) · cosponsor
- Salinas, Andrea (D · house · OR-6) · cosponsor
- Thanedar, Shri (D · house · MI-13) · cosponsor
Activity
Every typed-graph event involving this entity, newest first. Each row is one edge in the influence graph; click the date to jump to its provenance.
- 2026-05-17 · cosponsored by Thanedar, Shri (cosponsor) · sponsorship
- 2026-05-17 · cosponsored by Salinas, Andrea (cosponsor) · sponsorship
- 2026-05-17 · cosponsored by Gray, Adam (cosponsor) · sponsorship
- 2026-05-17 · cosponsored by Davis, Donald G. (cosponsor) · sponsorship
- 2026-05-17 · cosponsored by Hern, Kevin (cosponsor) · sponsorship
- 2026-01-01 · lobbied on by ALNYLAM PHARMACEUTICALS, INC. (h.r. 946) · lobbying_bill_mention
- 2026-01-01 · lobbied on by LUNDBECK LLC (h.r. 946) · lobbying_bill_mention
- 2026-01-01 · lobbied on by EMD SERONO, INC. (h.r. 946) · lobbying_bill_mention
- 2026-01-01 · lobbied on by INCYTE CORPORATION (h.r.946) · lobbying_bill_mention
- 2026-01-01 · lobbied on by CALIFORNIA LIFE SCIENCES (h.r.946) · lobbying_bill_mention
- 2026-01-01 · lobbied on by ALKERMES, INC. (h.r.946) · lobbying_bill_mention
- 2026-01-01 · lobbied on by ALNYLAM PHARMACEUTICALS, INC. (h.r.946) · lobbying_bill_mention
- 2026-01-01 · lobbied on by ASTRAZENECA (h.r. 946) · lobbying_bill_mention
- 2026-01-01 · lobbied on by IONIS PHARMACEUTICALS, INC. (h.r.946) · lobbying_bill_mention
- 2026-01-01 · lobbied on by INCYTE CORPORATION (h.r. 946) · lobbying_bill_mention
- 2025-01-03 · was referred to House Energy and Commerce Committee · congress-committee
- 2025-01-03 · was referred to House Ways and Means Committee · congress-committee